Literature DB >> 15210166

Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model.

Markus Wehner1, Henrik Rueffert, Fritjoff Koenig, Derk Olthoff.   

Abstract

Malignant hyperthermia (MH) is a pharmacogenetic disorder with an autosomal dominant inheritance. During exposure to triggering agents as volatile anaesthetics, affected individuals may develop a potentially fatal hypermetabolic syndrome caused by excessive calcium release from the sarcoplasmic reticulum in skeletal muscle. More than 60 MH associated mutations were found in the gene of skeletal muscle ryanodine receptor (RyR1), but only some of them have been functionally characterized. Primary human myotubes were cultured from carriers of RyR1 mutations in exon 44 (Ala2350Thr, Arg2355Trp, Gly2375Ala) and from MH non-susceptible individuals. Investigation of calcium homeostasis with the calcium sensitive probe Fura 2 showed a higher sensitivity to the ryanodine receptor agonists 4-chloro-m-cresol, caffeine and halothane for the myotubes derived from the mutation carriers as compared to those of the control group. The presence of RyR1 mutations with impact on calcium homeostasis emphasizes the functional significance of exon 44.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210166     DOI: 10.1016/j.nmd.2004.03.011

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  5 in total

Review 1.  Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels.

Authors:  Silvia G Priori; Carlo Napolitano
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

2.  Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States.

Authors:  Barbara W Brandom; Saiid Bina; Cynthia A Wong; Tarina Wallace; Mihaela Visoiu; Paul J Isackson; Georgirene D Vladutiu; Nyamkhishig Sambuughin; Sheila M Muldoon
Journal:  Anesth Analg       Date:  2013-04-04       Impact factor: 5.108

3.  Assessing the pathogenicity of RYR1 variants in malignant hyperthermia.

Authors:  A Merritt; P Booms; M-A Shaw; D M Miller; C Daly; J G Bilmen; K M Stowell; P D Allen; D S Steele; P M Hopkins
Journal:  Br J Anaesth       Date:  2017-04-01       Impact factor: 9.166

Review 4.  Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.

Authors:  Tokunbor A Lawal; Emily S Wires; Nancy L Terry; James J Dowling; Joshua J Todd
Journal:  Orphanet J Rare Dis       Date:  2020-05-07       Impact factor: 4.123

Review 5.  Malignant hyperthermia.

Authors:  Henry Rosenberg; Mark Davis; Danielle James; Neil Pollock; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2007-04-24       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.